27 October 2026
INTerpath-001 has given the field its first positive Phase 3 trial of an individualized neoantigen therapy. For biotech leaders developing the next generation of cancer vaccines, the more useful lesson is not that the approach can work, but what it takes to prove it.
At the ESMO 2026 Presidential Symposium in Madrid, investigators presented the full INTerpath-001 results for intismeran autogene (V940/mRNA-4157), the mRNA-based individualized neoantigen therapy developed by MSD and Moderna. The trial randomized 1,137 patients with completely resected stage IIB–IV melanoma 2:1 to intismeran plus pembrolizumab or placebo plus pembrolizumab. At a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42% (HR 0.58) and the risk of distant metastasis or death by 38% (HR 0.62), with similar rates of grade 3–5 treatment-related adverse events. It is the first positive late-stage result for an individualized neoantigen therapy, and it is consistent with the five-year Phase 2b KEYNOTE-942 data, in which 68.8% of patients on the combination remained recurrence-free versus 49.1% on pembrolizumab alone.
Overall survival is not yet mature and intismeran remains investigational. Even so, the result changes the conversation. For much of the past 30 years, therapeutic cancer vaccines were a story of strong immunology, encouraging Phase 2 signals and disappointing confirmation. Our Executive Medical Director, Dr George Peoples, has seen that story from the inside: he founded the Department of Defense Cancer Vaccine Development Program in 2000 and has spent more than two decades discovering, developing and testing cancer vaccines in the clinic. The view from that experience is simple. INTerpath-001 shows the concept can deliver; it does not make the next program any easier. Read carefully, the trial’s own data point to the scientific, clinical and operational problems that decide whether a personalized vaccine succeeds or fails.
“The most important clinical message in INTerpath-001 is the first six months. There was no difference between the arms while patients were being immunized and the benefit emerged once immunity had been built. That is how these vaccines work: they need time and a low burden of disease. Trials must be designed around that biology, from patient selection and endpoints through to how we measure the immune response.” – Dr George E. Peoples, Executive Medical Director, Oncology Center of Excellence, Avance Clinical
| Measure | Intismeran + pembrolizumab vs placebo + pembrolizumab | What it tells developers |
|---|---|---|
| Two-year RFS (primary endpoint, ITT) | 82.2% vs 70.0%; HR 0.58 (95% CI 0.45–0.75) | A clinically meaningful absolute gain of 12.2 percentage points |
| Two-year DMFS (key secondary) | 88.5% vs 80.2%; HR 0.62 (95% CI 0.45–0.85) | The benefit extends to distant disease |
| RFS in the first six months | HR 0.99 (95% CI 0.66–1.49) | No separation during immunisation: the effect is delayed |
| RFS after six months (prespecified sensitivity analysis) | HR 0.42 (95% CI 0.30–0.58) | Supportive of a delayed effect; not the headline result |
| RFS, modified ITT (dosed patients only) | HR 0.51 (95% CI 0.39–0.67) | Patients lost before first dose dilute the effect |
| Grade 3–5 treatment-related AEs | 14.2% vs 13.4% | Added burden is mainly reactogenicity (pyrexia 52.2%, injection-site pain 51.0%) |
Source: Merck & Co., INTerpath-001 results presented at ESMO 2026, 22 October 2026.
A personalized vaccine is a different product for every patient, and each product is a hypothesis about which mutations the immune system will recognize. Prediction is still imperfect. In the Phase 1 trial of the individualized mRNA vaccine autogene cevumeran in resected pancreatic cancer, only 25 of 230 administered neoantigens (11%) induced T-cell responses detectable ex vivo, and half of the patients responded. Those responders had markedly longer recurrence-free survival than non-responders.
Two implications follow for sponsors. First, immune monitoring is not an exploratory add-on. FDA guidance on therapeutic cancer vaccines expects immune monitoring in early trials to help optimize dose and schedule and, in later trials, to describe the type, magnitude and duration of response and any correlation with clinical efficacy. That means assays chosen, qualified and bridged early, with sampling timed to the biology rather than to the visit schedule. Second, dose selection rarely follows the classical maximum tolerated dose model. Vaccine dose-response is often saturable, so dose and schedule decisions rest on immunogenicity, tolerability and feasibility together.
The manufacturing process is part of the science. In a randomized, double-blind Phase 2b trial of an autologous tumor lysate, particle-loaded dendritic cell (TLPLDC) vaccine in resected stage III/IV melanoma, reported by Dr Peoples and colleagues, the protocol let patients and investigators choose whether to give G-CSF before the blood draw used to generate dendritic cells. The overall intention-to-treat comparison was not significant. In the prespecified analysis by collection method, however, vaccine made without G-CSF was associated with 36-month disease-free survival of 55.8% versus 30.0% with placebo, while vaccine made after G-CSF performed similarly to placebo; the authors linked this to less mature dendritic cells. The lesson is uncomfortable but valuable: with personalized products, an operational choice made for convenience can become an efficacy variable. Lessons like this are rarely written into guidance documents. They come from having run the trials.
The most instructive number in INTerpath-001 may be the hazard ratio of 0.99 for the first six months. During immunization the two arms were indistinguishable; the separation came afterwards. This is what FDA anticipated in its 2011 guidance: anti-tumor immunity generally takes two to three months to develop, a delayed effect can make the average treatment effect smaller than expected, sample sizes may need to increase and the proportional hazards assumption may not hold. In practice this shapes five design decisions.
Population. Settings with no evidence of disease or minimal residual disease give a vaccine time to work, but recurrence endpoints mean more patients and longer follow-up. The design has to select patients with enough risk to generate events and enough time to respond.
Statistics. Event projections, interim timing and the primary analysis should allow for non-proportional hazards from the outset, with sensitivity analyses prespecified rather than added after unblinding. The post-six-month analysis in INTerpath-001 carries weight because it was prespecified.
Randomization to first dose. The modified ITT analysis, which excluded participants who did not receive at least one dose of intismeran or placebo as planned, gave an HR of 0.51 against 0.58 in the full ITT population. In the TLPLDC trial, 12% of patients recurred before completing the primary vaccine series and the target sample size was increased in response. Every week between surgery, randomization and first dose counts.
Controls and blinding. KEYNOTE-942 compared the combination with open-label pembrolizumab alone; INTerpath-001 was double-blind and placebo-controlled, with investigator-assessed RFS as the primary endpoint. Blinding a personalized product is demanding. In the TLPLDC trial, control patients received their own dendritic cells loaded with empty particles, so every randomized patient followed the same collection and manufacturing pathway. That rigor is what makes an investigator-assessed endpoint credible.
Safety attribution. With a checkpoint inhibitor backbone, sites need clear guidance to separate expected reactogenicity (pyrexia affected 52.2% of patients on the combination) from immune-related adverse events, so that patients are managed correctly and backbone therapy is not interrupted without need.
Operationally, a personalized vaccine trial is a series of patient-specific manufacturing campaigns that must fit inside a standard-of-care treatment window. Intismeran is designed from each patient’s tumor and normal DNA, and in KEYNOTE-942 patients needed available tissue and confirmation that their product could be made before randomization. That places several demands on the sponsor and its CRO.
Tissue starts in the operating room. Consent, specimen handling, pathology review and shipment often need to be agreed before surgery, when patients are not yet in the trial. That requires early engagement with surgical and pathology teams, not only with medical oncologists.
Timelines are clinical variables. Sequencing, neoantigen selection, manufacture, release and shipment must be synchronized with standard therapy and the vaccine schedule; in INTerpath-001, intismeran was given every three weeks for up to nine doses alongside pembrolizumab every six weeks. The TLPLDC program showed that autologous production can be reliable, with successful manufacture in all patients and a median delivery time of 18 days, but only when the process is tightly controlled.
Chain of identity and custody must be unbroken from tissue to injection, with patient-specific labeling, pharmacy procedures and reconciliation that site staff can follow under pressure.
Immune monitoring samples are perishable. Peripheral blood mononuclear cell (PBMC) collection, processing and cryopreservation windows should drive site selection as much as recruitment potential does.
Regulatory dossiers need a coherent story for a product that changes with every patient: how the design algorithm, manufacturing process and release testing are controlled, and how immune and clinical data will be connected. Early, specific dialogue with regulators and ethics committees shortens the path.
“In a personalized vaccine trial, every patient has their own supply chain. The surgeon, pathology laboratory, sequencing and manufacturing teams, pharmacy and clinic all have to work to the same clock, and a delay at any point can cost a patient their place in the trial. Getting that right is what turns a promising design into deliverable data.”
Wendy Hamon, Senior Vice President, Oncology Center of Excellence, Avance Clinical
None of these challenges is unsolvable, but they are solved in the design, not in the rescue. Many CROs can run an oncology trial. Fewer have designed vaccine trials, built immune monitoring strategies, worked through a negative intention-to-treat result and understood why. For sponsors, the practical test is whether a partner’s scientific and operational teams can answer questions like these together.
Table 2. Questions to ask a CRO partner for a personalized cancer vaccine program
| Area | Question to ask | What a strong answer includes |
|---|---|---|
| Mechanism | How will we know the vaccine is working before efficacy data mature? | A qualified assay plan, sampling timed to the biology and prespecified links between immune response and outcome |
| Dose and schedule | How will we choose dose and schedule without a maximum tolerated dose? | Immunogenicity, safety and feasibility criteria agreed before dosing starts |
| Statistics | How does the design handle a delayed treatment effect? | Event projections and analyses that allow for non-proportional hazards |
| Patient journey | What is our time from surgery to first dose, and where could we lose patients? | A mapped pathway with targets for tissue, manufacture and release, tracked in real time |
| Sites | Which sites can deliver tissue, PBMC processing and combination dosing? | Selection on surgical, pathology and laboratory capability, not recruitment estimates alone |
| Safety | How will sites separate reactogenicity from immune-related toxicity? | Clear algorithms, investigator training and medical monitoring experienced with checkpoint inhibitors |
The Avance Clinical Oncology Center of Excellence was built around that combination of science and delivery. It brings scientific, medical, regulatory and operational leadership together, with capabilities spanning complex early-phase designs (including adaptive and Bayesian dose escalation), translational and biomarker strategy, disciplined patient selection and oncology-focused site networks across Australia, New Zealand, Asia Pacific, North America and Europe. The team has delivered more than 260 oncology trials in five years.
Medical leadership comes from Dr Peoples, a surgical oncologist and physician-scientist whose Cancer Vaccine Development Program licensed four vaccines for commercial development, and who founded Cancer Insight (later LumaBridge), the oncology-focused CRO that is now part of Avance Clinical. In practical terms, sponsors work with a team that understands both why a neoantigen response might fail to translate into clinical benefit and why a tissue sample might fail to arrive on time. Avance supports programs from preclinical planning through Phase II, with the option to start in Australia and New Zealand and expand globally with one team throughout.
MSD and Moderna are already running nine Phase 2 and Phase 3 trials of intismeran, including three Phase 3 trials in non-small cell lung cancer. Behind them, many biotechs are taking personalized and off-the-shelf cancer vaccines into early clinical development. INTerpath-001 has given regulators, investors and investigators a reference point for what a convincing vaccine program looks like. The decisions that determine whether a program can meet that standard (which population, which assays, which sites and how fast from surgery to first dose) are made in Phase 1. That is where the right partner makes the biggest difference.
To discuss a cancer vaccine program with the Oncology Center of Excellence, contact Wendy Hamon, Senior Vice President, Oncology Center of Excellence, Avance Clinical, or visit avancecro.com/oncology-center-of-excellence.
Avance Clinical is a full-service Contract Research Organization (CRO) with clinical operations in Australia, New Zealand, Asia, North America, and Europe.
Level 22, 91 King William Street
Adelaide, SA
Australia 5000
Phone: +61 8 8249 4788
For all media enquiries: media@avancecro.com
